Erasmus student: Summer 2012.
The Akt pathway in oncology therapy and beyond (Review)
Int J Oncol, 53 (6), 2319-2331
Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading
Oncotarget, 8 (7), 10966-10979
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
Int J Oncol, 48 (3), 869-85